Carbidopa / levodopa (Crexont, Duopa, Rytary) — 2026 Medicare Part D coverage
carbidopa / levodopa — sold as Crexont, Duopa, Rytary, Sinemet: 23 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover carbidopa / levodopa?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| carbidopa 10 MG / levodopa 100 MG Oral Tablet generic · RxCUI 197443 | 328 (100%) | 2 | 0 | 0 | 0 |
| carbidopa 25 MG / levodopa 100 MG Extended Release Oral Tablet generic · RxCUI 308988 | 328 (100%) | 2 | 0 | 0 | 2 |
| carbidopa 25 MG / levodopa 100 MG Oral Tablet generic · RxCUI 197444 | 328 (100%) | 2 | 0 | 0 | 0 |
| carbidopa 25 MG / levodopa 250 MG Oral Tablet generic · RxCUI 197445 | 328 (100%) | 2 | 0 | 0 | 0 |
| carbidopa 50 MG / levodopa 200 MG Extended Release Oral Tablet generic · RxCUI 308989 | 328 (100%) | 2 | 0 | 0 | 2 |
| carbidopa 10 MG / levodopa 100 MG Disintegrating Oral Tablet generic · RxCUI 483090 | 308 (94%) | 2 | 0 | 0 | 0 |
| carbidopa 25 MG / levodopa 100 MG Disintegrating Oral Tablet generic · RxCUI 476399 | 308 (94%) | 2 | 0 | 0 | 0 |
| carbidopa 25 MG / levodopa 250 MG Disintegrating Oral Tablet generic · RxCUI 476515 | 308 (94%) | 2 | 0 | 0 | 0 |
| RYTARY 23.75 MG / 95 MG 8HR Extended Release Oral Capsule brand · RxCUI 1600774 | 56 (17%) | 4 | 1 | 31 | 2 |
| RYTARY 36.25 MG /145 MG 8HR Extended Release Oral Capsule brand · RxCUI 1600776 | 56 (17%) | 4 | 1 | 31 | 2 |
| RYTARY 48.75 MG / 195 MG 8HR Extended Release Oral Capsule brand · RxCUI 1600915 | 56 (17%) | 4 | 1 | 31 | 2 |
| RYTARY 61.25 MG / 245 MG 8HR Extended Release Oral Capsule brand · RxCUI 1600917 | 56 (17%) | 4 | 1 | 31 | 2 |
| carbidopa 23.75 MG / levodopa 95 MG 8HR Extended Release Oral Capsule generic · RxCUI 1600773 | 15 (5%) | 4 | 0 | 6 | 6 |
| carbidopa 36.25 MG / levodopa 145 MG 8HR Extended Release Oral Capsule generic · RxCUI 1600775 | 15 (5%) | 4 | 0 | 6 | 6 |
| carbidopa 48.75 MG / levodopa 195 MG 8HR Extended Release Oral Capsule generic · RxCUI 1600914 | 15 (5%) | 4 | 0 | 6 | 6 |
| carbidopa 61.25 MG / levodopa 245 MG 8HR Extended Release Oral Capsule generic · RxCUI 1600916 | 15 (5%) | 4 | 0 | 6 | 6 |
| Duopa 4.63 MG / 20 MG in 1 mL Enteral Suspension brand · RxCUI 1599852 | 5 (2%) | 4 | 5 | 0 | 1 |
| CREXONT 35 MG / 140 MG Extended Release Oral Capsule brand · RxCUI 2690265 | 4 (1%) | 4 | 0 | 0 | 0 |
| CREXONT 52.5 MG / 210 MG Extended Release Oral Capsule brand · RxCUI 2690281 | 4 (1%) | 4 | 0 | 0 | 0 |
| CREXONT 70 MG / 280 MG Extended Release Oral Capsule brand · RxCUI 2690286 | 4 (1%) | 4 | 0 | 0 | 0 |
| CREXONT 87.5 MG / 350 MG Extended Release Oral Capsule brand · RxCUI 2690292 | 4 (1%) | 4 | 0 | 0 | 0 |
| SINEMET 10 MG / 100 MG Oral Tablet brand · RxCUI 724606 | 1 (0%) | 1 | 0 | 0 | 0 |
| Sinemet 25 MG / 100 MG Oral Tablet brand · RxCUI 724598 | 1 (0%) | 1 | 0 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.